Definitive Contract 75N93019C00039
Award Date
9/16/19
Potential Completion Date
5/31/22
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Epitogenesis Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
VERNON ROCKVL, CT 06066, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $4,148,210.00 Firm Fixed Price Definitive Contract to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, for the development of membrane-anchored cytokines as novel vaccine adjuvants for the elderly. This contract, which has a completion date of December 31, 2022, is part of the agency's "DEVELOPMENT OF MEMBRANE ANCHORED...
This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $600,000 firm-fixed-price definitive contract to Integral Molecular Inc., a small business biotechnology company, for "ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES." The contract has a completion date of June 29, 2024. Integral Molecular specializes in membrane protein research and has received numerous federal contracts and grants from agencies like the National Institutes of...
This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...
This is a $3,295,688.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Bluewillow Biologics Inc., a small business. The contract is for the development of NanoVax, an oil-in-water nanoemulsion adjuvant formulated with allergens as intranasal immunotherapeutic vaccines for peanut allergy. This contract is part of the Small Business Innovation Research (SBIR) program and represents...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...